An Asimov platform licensing agreement will give South Korea-based LG Chem access to the Boston company's CHO Edge System for biologics cell line development. Asimov announced the agreement on October 21, 2026.
Key Takeaways
- LG Chem will in-license Asimov's CHO Edge System to support biologics cell line development.
- The system includes the recently announced Chrysalis transposase and Kernel genetic design software.
- Asimov's CEO linked the agreement to developers' work on increasingly complex therapeutic molecules.
Table of Contents
- Asimov platform combines cell development tools and AI
- Agreement connects two therapeutic development businesses
- Conclusion
Asimov platform combines cell development tools and AI
The licensed system includes Chrysalis, Asimov's recently announced transposase, alongside Kernel, its AI-driven genetic design software. These components will support LG Chem's biologics cell line development activities.
Asimov co-founder and CEO Alec Nielsen placed the agreement in the context of drug developers exploring a wider range of therapeutic designs. He cited multispecific antibodies, fusion proteins and antibody drug conjugates as examples of increasingly complex molecules, and described CHO Edge as an enabler for LG Chem's next generation of therapeutic biologics.
Agreement connects two therapeutic development businesses
LG Chem operates across petrochemicals, advanced materials and life sciences. Its LG Chem Life Sciences division develops and delivers medicines across a broad range of therapeutic areas.
Asimov develops a synthetic biology platform spanning cells and software for the design and manufacture of therapeutics, including biologics, cell and gene therapies, and RNA. Founded by bioengineers from MIT and Boston University, the company says it has raised more than $200 million from institutional investors.
Conclusion
The agreement establishes LG Chem's planned use of CHO Edge to support biologics cell line development, combining Asimov's biological tools with its AI-driven genetic design software.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
